We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Lab 21 Acquires Independent Clinical Laboratory Diagnostics Company

By Labmedica staff writers
Posted on 31 Mar 2008
Print article
Lab21 (Cambridge, UK) has acquired NPTech Ltd. (Suffolk, UK), an independent clinical laboratory company providing diagnostic testing services for the UK National Health Service (NHS; UK) and private healthcare providers in the United Kingdom and parts of Europe. The financial terms of the transaction were not disclosed.

A global provider of diagnostic products and services, Lab21 supports drug discovery, healthcare, and environmental monitoring. Its customers include healthcare providers, pharmaceutic and biotechnology companies, in addition to organizations that need to monitor their impact on the environment. The company has a growing test portfolio providing companion diagnostics and high technology assays for the growing integration of personalized medicine into healthcare. These services and products are currently in infectious diseases, oncology, and pharmacogenetics areas with emerging interests in cardiovascular and metabolic disease.

The acquisition of NPTech significantly broadens Lab21's range of diagnostic tests. NPTech brings food intolerance testing; chemical and mold sensitivity testing; blood tests for a range of conditions; basic clinical chemistry; and salivary hormone testing. NPTech has multiple other diagnostic tests for a variety of clinical disorders including salivary tests for adrenal hormones, sex hormones, and sleep disturbance together with a range of clinical biochemistry blood testing, particularly in the area of thyroid disease diagnosis and management.

NPTech has a diverse range of international customers. Not only does the acquisition extend Lab21 interests into the allergy market, it also significantly develops its underlying clinical chemistry capability to support its cutting-edge products.

Graham Mullis, CEO of Lab21, said: "This is an excellent acquisition for Lab21. NPTech's range of services complement those already offered by Lab21, and will significantly enhance the range of tests we can offer. I am also delighted that NPTech is the first of what will be a number of acquisitions during 2008.”


Related Links:
Lab21
NPTech
National Health Service
New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Automated Blood Typing System
IH-500 NEXT
New
PSA Test
Human Semen Rapid Test
New
Silver Member
Oncology Molecular Diagnostic Test
BCR-ABL Dx ELITe MGB Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.